Skip to main content
SpringerLink
Log in

Opportunities for Pharmacists to Aid in the Management of Acid-Peptic Disorders

  • Practical Disease Management
  • Published:
Disease Management & Health Outcomes

Abstract

There is increasing evidence that pharmacists practicing in a myriad of clinical settings, including outpatient clinics and community pharmacies, can play a key role in efforts to manage many chronic diseases. This is especially true for conditions that are prevalent, costly, and where patients frequently self-medicate using over-the-counter drugs. The acid-peptic disorders (e.g. peptic ulcer disease, gastroesophageal reflux, and reflux esophagitis) meet these criteria and present pharmacists with an ideal opportunity to improve patient outcomes, acting independently or as part of a more comprehensive disease management initiative. The opportunity exists for pharmacists to enhance the care of patients with acid-peptic disorders by identifying patients who have one of these conditions, assessing their risk for serious diagnoses (e.g. cancer) or complications (e.g. bleeding), educating patients on self management, and optimizing medical regimens through collaboration with physicians. The major barrier for integrating pharmacists into disease management programs is reimbursement; however, some patients may be willing to pay for these services, and innovative payors may begin to provide compensation to pharmacists, Pharmacists should play a key role in new disease management models designed for conditions, such as acid-peptic disorders, that meet the criteria discussed in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Navarro RP, Cahill JA. The US health care system and the development of managed care. In: Navarro RP, editor. Managed care pharmacy practice. Gaithersburg (MD): Aspen Publishers Inc., 1999: 3–28

    Google Scholar 

  2. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43

    PubMed  CAS  Google Scholar 

  3. Bennett MS, Blank D, Bopp J, et al. Strategies to improve compensation for pharmaceutical care services. J Am Pharm Assoc (Wash) 2000; 40: 747–55

    CAS  Google Scholar 

  4. Ferro LA, Marcrom RE, Garrelts L, et al. Collaborative practice agreements between pharmacists and physicians. J Am Pharm Assoc (Wash) 1998 Nov–Dec; 38(6): 655–64; quiz 664–6

    CAS  Google Scholar 

  5. Koch KE. Trends in collaborative drug therapy management. Drug Benefit Trends 2000; 12(1): 45–54

    Google Scholar 

  6. Carter BL, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens (Greenwich) 2003; 5(1): 31–7

    Article  Google Scholar 

  7. McGhan WF, Stimmel GL, Hall TG, et al. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care 1983; 21(4): 435–44

    Article  PubMed  CAS  Google Scholar 

  8. Park JJ, Kelly P, Carter BL, et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996; 36(7): 443–51

    Google Scholar 

  9. Carter BL, Barnette DJ, Chrischilles E, et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997; 17(6): 1274–5

    PubMed  CAS  Google Scholar 

  10. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002; 22(10): 1294–300

    Article  PubMed  Google Scholar 

  11. Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists’ clinical services. Am J Health Syst Pharm 2001; 58: 569–77

    PubMed  CAS  Google Scholar 

  12. Lipton HL, Bird JA. The impact of clinical pharmacists’ consultations on geriatric patients’ compliance and medical care use: a randomized controlled trial. Gerontologist 1994; 34: 307–15

    Article  PubMed  CAS  Google Scholar 

  13. Kelso TM, Abou-Shala N, Heilker GM, et al. Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Am J Med Sci 1996; 311: 272–80

    Article  PubMed  CAS  Google Scholar 

  14. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 1977; 34: 1238–42

    PubMed  CAS  Google Scholar 

  15. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long term clinical and economic outcomes of a community-based diabetes program. J Am Pharm Assoc (Wash) 2003 Mar–Apr; 43(2): 173–84

    Article  Google Scholar 

  16. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641–7

    Article  PubMed  CAS  Google Scholar 

  17. Munroe WP, Kunz K, Dalmady-Israel C, et al. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther 1997; 19: 113–23

    Article  PubMed  CAS  Google Scholar 

  18. Navarro RP, Christensen D, Leider H. Disease management programs. In: Navarro RP, editor. Managed care pharmacy practice. Gaithersburg (MD): Aspen Publishers Inc., 1999: 371–95

    Google Scholar 

  19. Katz PO, Castell DO. Management issues in gastroesophageal reflux disease: the dilemma of Barrett’s esophagus: old questions, new answers [online]? Available from URL: http://www.medscape.com/viewprogram/617?src=search [Accessed 1 May 2003]

  20. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 579–81

    Article  Google Scholar 

  21. McQuaid KR. Etiology and Management of functional dyspepsia: abandon all hope ye who study here. Presentation at Digestive Disease Week; 2000 May 23; San Diego

    Google Scholar 

  22. Pinson JB, Weart CW. Acid-peptic products. In: Covington TR, Berardi RR, Young LL, et al., editors. Handbook of nonprescription drugs. Washington, DC: American Pharmaceutical Association, 2002: 193–224

    Google Scholar 

  23. ASHP Commission on Therapeutics. ASHP therapeutic position statement on the identification and treatment of Helicobacter-associated peptic ulcer disease in adults. Am J Health Syst Pharm 2001; 58(4): 331–7

    Google Scholar 

  24. Howden CW, Hunt RW. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330–8

    Article  PubMed  CAS  Google Scholar 

  25. Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease. Philadelphia (PA): WB Saunders Company, 1998: 498–507

    Google Scholar 

  26. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998; 93: 1800–2

    Article  PubMed  CAS  Google Scholar 

  27. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Consensus statement: medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996; 275: 622–9

    Article  PubMed  CAS  Google Scholar 

  28. Schoenfield P. Management issues is acid-peptic disorders [online]. Available from URL: http://www.medscape.com/newprogram/388 [Accessed 1 May 2003]

  29. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037–46

    Article  PubMed  CAS  Google Scholar 

  30. Oliveria SA, Christos PJ, Talley NJ, et al. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med 1999; 159: 1592–8

    Article  PubMed  CAS  Google Scholar 

  31. Berardi RR. Peptic ulcer disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. New York: Appleton & Lange, 1999: 548–70

    Google Scholar 

  32. Levin TR, Schmittdiel JA, Kurz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997; 103: 20–8

    Article  Google Scholar 

  33. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8

    Article  PubMed  CAS  Google Scholar 

  34. Orlando RC. Reflux esophagitis. In: Yamada T, Alpers DH, Owyang C, et al., editors. Textbook of gastroenterology. 2nd ed. Philadelphia (PA): JB Lippincott Company, 1995; 1214–42

    Google Scholar 

  35. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52–60

    CAS  Google Scholar 

  36. AstraZeneca. Nexium™ (esomeprazole magnesium) product insert. Wilmington (DE): AstraZeneca, 2001 Feb

    Google Scholar 

  37. Tap Pharmaceutical Products, Inc. Prevacid® (lansoprazole) product insert. Lake Forest (IL): Tap Pharmaceutical Products, Inc., 2000 Nov

    Google Scholar 

  38. AstraZeneca. Prilosec® (omeprazole) product insert. Wilmington (DE): Astra-Zeneca, 2000 Apr

    Google Scholar 

  39. Lamouliatte H, Cayla R, Zerbib F, et al. Triple therapy with PPI-amoxicillinclarithromycin for H. pylori eradication: the optimal regimen in 1996. Gastroenterology 1996; 110: A171

    Google Scholar 

  40. Battle EH, Peura DA. New guidelines for the detection and treatment of H. pylori infection. Infect Med 1999; 16(5): 337–41

    Google Scholar 

  41. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434–42

    Article  PubMed  CAS  Google Scholar 

  42. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(9 Suppl.): S491–505

    PubMed  CAS  Google Scholar 

  43. Williams DB. Gastroesophageal reflux disease. In: DePiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1999: 532–47

    Google Scholar 

  44. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. 1994 Jul 6; 272(1): 65–9

    Google Scholar 

  45. National Heartburn Alliance. Pharmacists and their interactions with heartburn sufferers: executive summary of survey results. Arlington Heights (IL): Market Facts, 2000

    Google Scholar 

  46. Schoen MD. Lipid management: an opportunity forpharmacy service. J Am Pharm Assoc (Wash) 1999; 39(3): 1–10

    Google Scholar 

  47. Wyeth Laboratories, Protonix [package insert]. Philadelphia (PA): Wyeth Laboratories, 2002 Mar 29

  48. Eisai Inc. Aciphex [package insert]. Teaneck (NJ): Eisai Inc, 2002 Apr

  49. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000 Oct; 39(4): 295–309

    Article  PubMed  CAS  Google Scholar 

  50. Merck & Co., Inc. Pepcid Complete [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.

  51. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983–8

    Article  PubMed  CAS  Google Scholar 

  52. Cohen S, Parkman HP. Heartburn: a serious symptom. N Engl J Med 1999; 340(11): 878–9

    Article  PubMed  CAS  Google Scholar 

  53. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. JCOM 2000; 7: 29–34

    Google Scholar 

  54. Eliakim R, Abulafia O, Sheer DM. Estrogen, progesterone and the gastrointestinal tract. J Reprod Med 2000 Oct; 45(10): 781–8

    PubMed  CAS  Google Scholar 

  55. Scheiman JM. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Am J Manag Care 2001; 7(1 Suppl.): S10–8

    PubMed  CAS  Google Scholar 

  56. Yanchick JK. Implementation of a drug therapy monitoring clinical in a primary care setting. Am J Health Syst Pharm 2000; 57 Suppl. 4: S30–7

    PubMed  Google Scholar 

  57. Levin TR, Schmittdiel JA, Henning JM, et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998; 93: 743–7

    Article  PubMed  CAS  Google Scholar 

  58. Wilkinson SP, Biddlestone L, Gore S, et al. Regression of columnar-lined Barrett’s esophagus with omeprazole 40mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 1205–9

    Article  PubMed  CAS  Google Scholar 

  59. Rabeneck L, Cook KF, Wristers K, et al. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 2001; 54: 755–65

    Article  PubMed  CAS  Google Scholar 

  60. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8

    Article  PubMed  CAS  Google Scholar 

  61. Dean BB, Siddique RM, Yamashita BD, et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy or erosive reflux esophagitis. Am J Health Syst Pharm 2001; 58: 1338–46

    PubMed  CAS  Google Scholar 

  62. DeVault KR, Castell D. Practice guidelines: updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999 Jun; 94(6): 1434–42

    Article  PubMed  CAS  Google Scholar 

  63. Patchin GM, Wieland KA, Carmichael JM. Six-months’ experience with a pharmacist-run H. pylori treatment clinic. Am J Hosp Pharm 1996; 53: 2081–2

    CAS  Google Scholar 

  64. Morreale AP. Pharmacist-managed Helicobacter pylori clinic. Am J Hosp Pharm 1995; 52: 183–5

    CAS  Google Scholar 

  65. Jones GT, Morreale AP. Cost-benefit computer modeling of Helicobacter pylori testing and treatment in patients on long-term H2-blocker prophylaxis. J Manag Care Pharm 2000; 6: 383–9

    Google Scholar 

  66. Bennett MS, Blank D, Bopp J, et al. Strategies to improve compensation for pharmaceutical care services. J Am Pharm Assoc (Wash) 2000; 40: 747–55

    CAS  Google Scholar 

  67. Sias JJ, Bennett MS. A reimbursable education service for patients with hepatitis C. J Am Pharm Assoc (Wash) 2001 May–Jun; 41: 448–52

    CAS  Google Scholar 

  68. American Pharmaceutical Association. Emergency contraception: the pharmacist’s role. APhA special report. Washington, DC: American Pharmaceutical Association, 2000 May

    Google Scholar 

  69. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc (Wash) 2000; 40: 157–65

    CAS  Google Scholar 

Download references

Acknowledgments

AstraZeneca provided an unrestricted educational grant for the preparation of this article.

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Medical University of South Carolina, South Carolina, USA

    C. Wayne Weart

  2. Thomas Jefferson University, Philadelphia, Pennsylvania, USA

    Harry Leider (Senior Vice President)

  3. Interactive Forums Inc., 150 Monument Road, Suite 610, Bala Cynwyd, Pennsylvania, 19004, USA

    Harry Leider (Senior Vice President)

Authors
  1. C. Wayne Weart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry Leider
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weart, C.W., Leider, H. Opportunities for Pharmacists to Aid in the Management of Acid-Peptic Disorders. Dis-Manage-Health-Outcomes 12, 239–247 (2004). https://doi.org/10.2165/00115677-200412040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200412040-00004

Keywords

Search

Navigation